Since CD19 may not cover all types of lymphoma subclones,428–430 CAR-T cells targeting other highly-specific antigens and dual targets,302,431–437 such as CD22, CD19/CD20, and CD30, have been developed as well. This evidence concerns the gene CD19 and lymphoma.